Item 9 Labs Corp
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies thr… Read more
Item 9 Labs Corp (INLB) - Total Assets
Latest total assets as of June 2023: $112.02 Million USD
Based on the latest financial reports, Item 9 Labs Corp (INLB) holds total assets worth $112.02 Million USD as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Item 9 Labs Corp - Total Assets Trend (2010–2022)
This chart illustrates how Item 9 Labs Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Item 9 Labs Corp - Asset Composition Analysis
Current Asset Composition (September 2022)
Item 9 Labs Corp's total assets of $112.02 Million consist of 3.2% current assets and 96.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $586.27K | 0.5% |
| Inventory | $2.46 Million | 2.2% |
| Property, Plant & Equipment | $21.96 Million | 19.8% |
| Intangible Assets | $11.74 Million | 10.6% |
| Goodwill | $58.23 Million | 52.6% |
Asset Composition Trend (2010–2022)
This chart illustrates how Item 9 Labs Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Item 9 Labs Corp's current assets represent 3.2% of total assets in 2022, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2022, down from 1.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 52.6% of total assets.
Item 9 Labs Corp Competitors by Total Assets
Key competitors of Item 9 Labs Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Item 9 Labs Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Item 9 Labs Corp generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Item 9 Labs Corp is currently not profitable relative to its asset base.
Item 9 Labs Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.14 | 3.32 |
| Quick Ratio | 0.02 | 0.04 | 3.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-55.47 Million | $ -33.78 Million | $ 2.28 Million |
Item 9 Labs Corp - Advanced Valuation Insights
This section examines the relationship between Item 9 Labs Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | $110.76 Million |
| Market Capitalization | $10.08K USD |
Valuation Analysis
Below Book Valuation: The market values Item 9 Labs Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Item 9 Labs Corp's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Item 9 Labs Corp (2010–2022)
The table below shows the annual total assets of Item 9 Labs Corp from 2010 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-09-30 | $110.76 Million | -5.18% |
| 2021-09-30 | $116.81 Million | +465.28% |
| 2020-09-30 | $20.66 Million | +42.76% |
| 2019-09-30 | $14.47 Million | +312.05% |
| 2018-09-30 | $3.51 Million | +3133.38% |
| 2017-09-30 | $108.64K | +21.77% |
| 2016-09-30 | $89.22K | -20.81% |
| 2015-09-30 | $112.67K | -77.85% |
| 2014-09-30 | $508.66K | +14.96% |
| 2013-09-30 | $442.45K | -61.16% |
| 2012-09-30 | $1.14 Million | +5511.73% |
| 2011-09-30 | $20.30K | 0.00% |
| 2010-09-30 | $20.30K | -- |